SCHEMBL1397667

SCHEMBL1397667

CC=Cc1cccc(OC(C)(C)OCCC)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR4 O00206 1/20 0.41
TLR2 O60603 1/20 0.41
FBP1 P09467 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.38
ALDH1A1 P00352 2/20 0.38
KDM4E B2RXH2 1/20 0.38
RELA Q04206 1/20 0.37
NFE2L2 Q16236 3/20 0.36
CHRNA7 P36544 1/20 0.35
CYP19A1 P11511 1/20 0.35
NQO2 P16083 1/20 0.35
HPGD P15428 1/20 0.35
ATM Q13315 1/20 0.35
TUBB4A P04350 1/20 0.34
TUBB P07437 1/20 0.34
TUBA3C P0DPH7 1/20 0.34
TUBA1B P68363 1/20 0.34
TUBA4A P68366 1/20 0.34
TUBB4B P68371 1/20 0.34
TUBB3 Q13509 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1397179 0.90 FBP1 (0.43) TLR4TLR2FBP1SMN1; SMN2ALDH1A1
SCHEMBL1360519 0.84 TP53 (0.40) TLR4TLR2FBP1SMN1; SMN2ALDH1A1
SCHEMBL1397219 0.82 LCK (0.48) TLR4TLR2FBP1SMN1; SMN2ALDH1A1
SCHEMBL29602276 0.81 RELA (0.45) FBP1ALDH1A1KDM4ERELANFE2L2
SCHEMBL1358879 0.81 RELA (0.45) FBP1ALDH1A1KDM4ERELANFE2L2
SCHEMBL1397736 0.78 FBP1 (0.42) TLR4TLR2FBP1SMN1; SMN2ALDH1A1
SCHEMBL1361508 0.78 RELA (0.38) FBP1SMN1; SMN2ALDH1A1KDM4ERELA
SCHEMBL1397270 0.78 RELA (0.38) FBP1SMN1; SMN2ALDH1A1KDM4ERELA
SCHEMBL28733922 0.78 TLR4 (0.51) TLR4TLR2SMN1; SMN2ALDH1A1KDM4E
SCHEMBL29602926 0.78 RELA (0.38) FBP1SMN1; SMN2ALDH1A1KDM4ERELA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107229185-B Energy-sensitive composition, cured product, and method for producing cured product 东京应化工业株式会社 2022-04-15 CN disclosed
CN-107207456-B Latent acids and their use 巴斯夫欧洲公司 2021-05-04 CN disclosed
EP-3253735-B1 LATENT ACIDS AND THEIR USE BASF SE (DE) 2021-03-31 EP disclosed
EP-2539316-B1 LATENT ACIDS AND THEIR USE BASF SE (DE) 2019-10-23 EP disclosed
US-9994538-B2 Latent acids and their use BASF SE (DE) 2018-06-12 US disclosed
US-20180009775-A1 LATENT ACIDS AND THEIR USE BASF SE (DE) 2018-01-11 US disclosed
WO-2016124493-A1 LATENT ACIDS AND THEIR USE BASF SE (DE) 2016-08-11 WO disclosed
EP-1595182-B1 HALOGENATED OXIME DERIVATIVES AND THE USE THEREOF AS LATENT ACIDS BASF SE (DE) 2015-09-30 EP disclosed
EP-1769286-B1 OXIME DERIVATIVES AND THE USE THEROF AS LATENT ACIDS BASF SE (DE) 2015-09-09 EP disclosed
US-9005871-B2 Sulfonium derivatives and the use therof as latent acids BASF SE (DE) 2015-04-14 US disclosed
EP-1392675-A1 SUBSTITUTED OXIME DERIVATIVES AND THE USE THEREOF AS LATENT ACIDS Ciba SC Holding AG (CH) 2004-03-03 EP disclosed
US-20040002007-A1 Oxime derivatives and the use thereof as latent acids CIBA SPECIALTY CHEMICALS CORP. 2004-01-01 US disclosed
EP-1344109-A2 ONIUM SALTS AND THE USE THEROF AS LATENT ACIDS Ciba SC Holding AG (CH) 2003-09-17 EP disclosed
WO-2003067332-A2 SULFONATE DERIVATIVES AND THE USE THEROF AS LATENT ACIDS CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2003-08-14 WO disclosed
EP-1320785-A2 OXIME DERIVATIVES AND THE USE THEREOF AS LATENT ACIDS Ciba SC Holding AG (CH) 2003-06-25 EP disclosed
US-6512020-B1 Photosensitive acid-donors in chemically amplified resist formulations. activated by irradiation with actinic electromagnetic radiation and electron beams. CIBA SPECIALTY CHEMICALS CORPORATION 2003-01-28 US disclosed
WO-2002098870-A1 SUBSTITUTED OXIME DERIVATIVES AND THE USE THEREOF AS LATENT ACIDS CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2002-12-12 WO disclosed
WO-2002046507-A2 ONIUM SALTS AND THE USE THEROF AS LATENT ACIDS CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2002-06-13 WO disclosed
WO-2002025376-A2 OXIME DERIVATIVES AND THE USE THEREOF AS LATENT ACIDS CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2002-03-28 WO disclosed
US-6261738-B1 LATENT CURING CATALYSTS FOR PHOTORESISTS SUCH AS 2,2,2-TRIFLUORO-1-PHENYL-ETHANONE OXIME-O-METHYL SULFONATE CIBA SPECIALTY CHEMICALS CORPORATION 2001-07-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180009775-A1 LATENT ACIDS AND THEIR USE LTA, C1S, C9 TLR4 1774/4885TLR2 1071/4885FBP1 3937/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.